Publication Digest

Meet the experts

Professor Stephen Nicholls

Professor Stephen Nicholls is the Program Director of MonashHeart and Intensive Care, Director of the Victorian Heart Institute and Professor of Cardiology at Monash University, Melbourne, Australia. He is the Director of the Victorian Heart Hospital. His research interests focus on the role of metabolic risk factors and imaging in atherosclerosis, with work spanning from early discovery to leadership of large clinical trials. He is President of the Cardiac Society of Australia and New Zealand, a lead investigator for the Australian Stroke and Heart Research Accelerator, Chair of the Asia Pacific Cardiometabolic Consortium and a Fellow of the Australian Academy of Health and Medical Sciences.

Disclosures: Research support, consulting and honoraria fees from Anthera Pharmaceuticals, AstraZeneca, Lilly, Resverlogix, Sanofi–Regeneron. Research support from Amgen, Cerenis Therapeutics (ABIONYX Pharma), Esperion Therapeutics, Infraredx, LipoScience, The Medicines Company, Novartis, Roche. Consulting and honoraria fees from Akcea Therapeutics, Boehringer Ingelheim, CSL Behring, Esperion Therapeutics, Merck, NewAmsterdam Pharma, Takeda.

Professor Kausik Ray

Kausik Ray is Professor of Public Health at the Department of Public Health and Primary Care, Imperial College London, and an honorary consultant cardiologist at the Imperial College NHS Trust, UK. He is currently President of the European Atherosclerosis Society, Chair of the World Heart Federation Cholesterol Roadmap 2021–2022, and Chair for Global Council for Heart Health. Professor Ray conducts research on lipids, diabetes mellitus and population health, and serves as a global lead for clinical trials and registries.

Disclosures: Advisor/consultant and speaker for Amgen, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Novartis, Novo Nordisk, Pfizer. Advisor/consultant for Abbott, Esperion, Kowa, Lilly, NewAmsterdam Pharma, Resverlogix, Silence Therapeutics, and as a speaker for Lupin and Sanofi. Stock options in Cargene Therapeutics and Pemi31 Therapeutics. His institution (Imperial College London) received clinical research grants from Amgen, Daiichi Sankyo, and Regeneron.

Professor Oliver Weingärtner

Professor Oliver Weingärtner is an interventional cardiologist at the University Hospital in Jena, Germany. He has been trained in general internal medicine, intensive care medicine, cardiology and angiology. As the current President of the German Society of Lipidology (DGFF), he has a special interest in cholesterol metabolism and cardiovascular risk prediction.

Disclosures: Honoraria for lectures from Akcea Therapeutics, Amarin, Amgen, Berlin-Chemie, Fresenius, Hexal, Novartis, Novo Nordisk, Sanofi. Honoraria for advisory board activities from Akcea Therapeutics, Amarin, Amgen, Berlin-Chemie, Hexal, Novartis, Pfizer, Sanofi. Participated in the conduct of the following clinical trials: Horizon Outcomes, AEGIS-II, Care High, VICTORION-Implement.

Professor Alberico Catapano

Alberico Catapano is Director of the Center for the Study, Prevention and Therapy of Atherosclerosis of the University of Milan at the Bassini Hospital, Italy; Director of the Cardiovascular Research Unit at MultiMedica IRCCS Sesto San Giovanni (MI); and Co-Chairman of the European Atherosclerosis Society (EAS)/European Society of Cardiology (ESC) guidelines for the treatment of dyslipoproteinaemias and lipid consensus papers. Professor Catapano is interested in the study of atherosclerosis, lipids, lipoproteins, and genetic dyslipidaemias, and he has made landmark observations regarding heat shock proteins and pentraxins in atherogenesis, and on high-density lipoproteins in the modulation of the immune response, and on the identification of possible therapeutic targets by exploiting genetic information.

Disclosures: Akcea Therapeutics, Amarin, Amgen, Amryt Pharma, AstraZeneca, Daiichi Sankyo, Esperion Therapeutics, Ionis Pharmaceuticals, Medscape Education, Menarini, Merck, Mylan, Novartis, PeerVoice, Pfizer, Recordati, Regeneron, Sanofi, The Corpus, Viatris.